Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Selskabsmeddelelse

MEDI: First quarter 2025 financial results and status for Medistim ASA

Medistim
An exceptionally strong quarter for sales revenues, 20.1 % above the previous
record, ending at MNOK 181.5. This is growth of 35.7 % compared to first quarter
last year (MNOK 133.8).

Currency neutral sales of own products were up 29.9 % for the quarter.

Strong growth in all geographies with AMERICAS up 28.4 %, EMEA up 18.2 % and
APAC up 62.6 %, currency neutral.

Third-party distributor sales in Scandinavia increased 41.2 % for the quarter.

Operating profit (EBIT) grew by 84.5 % and ended at MNOK 59.2 giving a 32.6 %
EBIT margin (MNOK 32.1, 24.0 % margin)

Recurring sales remained high, but strong capital sales reduce recurring sales
in percent to 68 % (75 %) compared to same quarter last year.

Medistim strengthened its commercial operation by appointing a Chief Commercial
Officer and a new VP Sales for AMERICAS.

Solid cash position at quarter end with MNOK 183.4 and no interest-bearing
liabilities.
The General Meeting decided a dividend of NOK 6.00 per share (NOK 4.5), total
MNOK 109.6 (MNOK 82.4).
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.